Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is scheduled to announce its earnings results after the market closes on Wednesday, July 26th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Thursday, April 27th. The medical device company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.66) by $0.09. Tandem Diabetes Care had a negative net margin of 104.31% and a negative return on equity of 1,177.11%. The firm had revenue of $17.50 million during the quarter, compared to the consensus estimate of $15.72 million. During the same period in the prior year, the business earned ($0.68) earnings per share. Tandem Diabetes Care’s quarterly revenue was down 12.9% compared to the same quarter last year. On average, analysts expect Tandem Diabetes Care to post $-1.88 EPS for the current fiscal year and $-1.29 EPS for the next fiscal year.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) opened at 0.61 on Wednesday. The firm has a 50-day moving average of $0.78 and a 200 day moving average of $1.48. The company’s market capitalization is $30.40 million. Tandem Diabetes Care, Inc. has a 12-month low of $0.56 and a 12-month high of $8.81.

TRADEMARK VIOLATION WARNING: This piece of content was first published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/19/tandem-diabetes-care-inc-tndm-to-release-quarterly-earnings-on-wednesday.html.

A number of brokerages have recently issued reports on TNDM. Wedbush reissued an “outperform” rating and issued a $11.00 price target on shares of Tandem Diabetes Care in a report on Thursday, March 30th. B. Riley downgraded shares of Tandem Diabetes Care to a “neutral” rating and set a $1.50 price target on the stock. in a report on Wednesday, March 29th. Cowen and Company downgraded shares of Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and set a $1.50 price target on the stock. in a report on Monday, April 10th. Finally, Piper Jaffray Companies reissued a “neutral” rating on shares of Tandem Diabetes Care in a report on Thursday, March 30th. Six analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $4.71.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Earnings History for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related companies with MarketBeat.com's FREE daily email newsletter.